Artemisinin Combination Therapy Market Size, Share, By Therapy Type (Artemether + Lumefantrine, Artesunate + Amodiaquine, Dihydroartemisinin + Piperaquine, Artesunate + Mefloquine, Artesunate + Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, and Others), End User (Hospitals, Clinics, Government Health Facilities, NGO & International Health Organization Programs, and Others), and Region - Trends, Analysis, and Forecast till 2035

By region, the Artemisinin Combination Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

The Artemisinin Combination Therapy (ACT) market was dominated by the North American area, which generated about 37.7% of global sales. The primary causes of this domination are the growing number of imported malaria cases among tourists and immigrants from endemic areas, as well as the region's robust public health regulations and well-established healthcare system, which guarantee efficient treatment choices.

The high prevalence of malaria, especially in nations including Vietnam, Indonesia, and India, as well as the growing number of drug-resistant forms of the disease are driving the fastest growth in the ACT market in the Asia Pacific region. Increased healthcare spending in the area and government programs to manage and eradicate malaria further increase demand for ACTs.

Europe's dedication to the worldwide endeavor to eradicate malaria and the rise in travel-related malaria cases are the main factors propelling the market for artemisinin combination therapy (ACT) in the area. Furthermore, healthcare policies and regulatory approvals that favor antimalarial treatments further accelerate market expansion.